Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes
2011

Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: Five-Year Outcomes

Sample size: 41 publication Evidence: high

Author Information

Author(s): Debra E Freeman, Christopher R King

Primary Institution: Naples Radiation Oncology, PA, USA; Department of Radiation Oncology, UCLA School of Medicine, CA, USA

Hypothesis

Does hypofractionated stereotactic body radiotherapy (SBRT) provide effective treatment outcomes for low-risk prostate cancer patients?

Conclusion

SBRT for localized prostate cancer shows high efficacy and safety with a 93% biochemical progression-free survival rate over five years.

Supporting Evidence

  • The biochemical progression-free survival rate was 93% at five years.
  • No grade 4 toxicities were reported.
  • Only one late grade 3 genitourinary toxicity occurred.

Takeaway

This study shows that a special type of radiation treatment for prostate cancer works really well and has very few side effects.

Methodology

Patients received SBRT with CyberKnife in five fractions, and outcomes were assessed using Kaplan-Meier survival analysis.

Limitations

The study only included low-risk patients and had a relatively small sample size.

Participant Demographics

Median age was 66 years, with a range from 48 to 83 years; all patients had low-risk prostate cancer.

Statistical Information

P-Value

0.002

Confidence Interval

95% CI = 84.7% to 100%

Statistical Significance

p=0.002

Digital Object Identifier (DOI)

10.1186/1748-717X-6-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication